Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

This study has been completed.
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00728598
First received: August 1, 2008
Last updated: August 5, 2008
Last verified: August 2008

August 1, 2008
August 5, 2008
January 1998
December 1998   (final data collection date for primary outcome measure)
Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor. [ Time Frame: vitreous sample collected on vitrectomy ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00728598 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.

Fractalkine (FKN) is a chemoattractant and adhesion molecule for leukocytes. Angiogenic effect of FKN also has been reported. We investigate FKN-mediated angiogenesis in ocular angiogenic disorders.

Fractalkine (FKN), the sole member of the CX3C chemokine family, is named for its fractal geometry. The CX3C motif, with three amino acids between the two terminal cysteines, makes fractalkine distinct from other chemokines.The structure of fractalkine, a membrane-bound glycoprotein with the chemokines domain atop an extended mucin-like stalk, also is unique.Membrane-bound FKN can be markedly induced on primary endothelial cells by inflammatory cytokines; this form promotes the robust adhesion of monocytes and T lymphocytes. Soluble FKN can be released by proteolysis at an efficient chemotactic activity level for monocytes and T cells. Thus, FKN is a versatile molecule regulating both cell-cell interactions in its membrane-bound form and directed-cell migration in its soluble form. The receptor of FKN, CXC3R1, is a G protein-couple protein, which expresses T lymphocytes, monocytes, natural killer (NK) cells, microglia, and neurons.Sulfation of tyrosine enhances the function of CX3CR1 in cell capture and firm adhesion. Fractalkine is expressed constitutively in the kidney, heart, lung, and brain. Fractalkine has demonstrated an important role in CNS inflammation, cardiac allograft rejection, arteriogenesis, renal disease, psoriasis, and during pregnancy. Silverman et al demonstrated the presence of FKN in normal cultured microvascular endothelial and stromal cells of iris and retina in vitro. Upon inflammatory cytokine stimulation, EC also express FKN and its receptors with FKN secretion in an autocrine manner. In addition to EC chemotaxis and tube formation, FKN is an angiogenic mediator in rheumatoid arthritis. Therefore, we hypothesize that FKN not only participates in ocular inflammatory reactions, but also plays an important role in ocular angiogenesis.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Vitreous sample and blood sample

Non-Probability Sample

Patients with proliferative diabetic retinopathy, who will receive vitrectomy.

  • Proliferative Diabetic Retinopathy
  • Angiogenesis
Not Provided
  • 1
    Proliferative diabetic retinopathy, active.
  • 2
    Proliferative diabetic retinopathy, quiescent.
  • 3
    Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
December 1998
December 1998   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • clinical diagnosis of proliferative diabetic retinopathy.
  • who will receive vitrectomy for treatment of disease.

Exclusion Criteria:

  • previous ocular surgical history.
  • history of uveitis
  • history of ocular trauma.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT00728598
9561702008
Not Provided
Not Provided
National Taiwan University Hospital
Not Provided
Principal Investigator: Chang-Hao Yang, MD, PhD Ophthalmology, National Taiwan University Hospital
National Taiwan University Hospital
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP